Cell Medica Opens Commercial Manufacturing Facility - - BioPharm International

ADVERTISEMENT

Cell Medica Opens Commercial Manufacturing Facility


Cell Medica, a T cell therapeutics company, has opened a European manufacturing facility in Berlin-Buch, Germany to develop, manufacture, and market treatments of infections and cancers related to oncogenic viruses.

Cell Medica’s commercial manufacturing facility at the Max-Delbrück-Center of Molecular Medicine within the biotechnology area of Campus Berlin-Buch includes approximately 350 m2 cleanroom space, and will initially focus on manufacturing the company’s Cytovir CMV. The Cytovir CMV treatment uses immune cells of a healthy donor to restore immunity to Cytomegalovirus infections in patients who have lost their immunity following a bone marrow transplant. The commercial launch of Cytovir CMV is planned for early 2014, following the completion of two randomized controlled studies currently ongoing in the UK.
  
The facility will also be important in providing investigational medicine products for Cell Medica’s planned CITADEL study to investigate a T cell therapy for the treatment of EBV-associated lymphomas, which will be undertaken following the required regulatory approvals, the company reports.

Source: Cell Medica

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here